WO2023021492 - STABLE CYCLOSPORINE OPHTHALMIC FORMULATION AND MANUFACTURING PROCESS THEREOF
National phase entry:
Publication Number
WO/2023/021492
Publication Date
23.02.2023
International Application No.
PCT/IB2022/057851
International Filing Date
22.08.2022
Title **
[English]
STABLE CYCLOSPORINE OPHTHALMIC FORMULATION AND MANUFACTURING PROCESS THEREOF
[French]
FORMULATION OPHTALMIQUE DE CYCLOSPORINE STABLE ET PROCÉDÉ DE FABRICATION ASSOCIÉ
Applicants **
SUN PHARMACEUTICAL INDUSTRIES LIMITED
Sun House, Plot No. 201 B/1
Western Express Highway
Goregaon (E)
Mumbai, Maharashtra 400 063, IN
Inventors
KHOPADE, Ajay Jaysingh
Sun Pharmaceutical Industries Limited
Survey No. 127/1, Tandalja
Vadodara, Gujarat 390020, IN
HALDER, Arindam
Sun Pharmaceutical Industries Limited
Survey No. 127/1, Tandalja
Vadodara, Gujarat 390020, IN
Priority Data
202121037917
20.08.2021
IN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
EPO
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 2009 | |
| EPO | Filing, Examination | 11758 | |
| Japan | Filing | 587 | |
| South Korea | Filing | 574 | |
| USA | Filing, Examination | 13310 |
Total: 28238 USD
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
A stable nanomicellar ophthalmic solution comprising cyclosporine and a method of preparing the nanomicellar solution. The present invention further relates to a stable nanomicellar solution comprising a cyclosporine form with characteristic XRD peaks at 2-theta (deg.) 6.9, 7.8, 9.4 and 15.9 or amorphous cyclosporine. The present invention also relates to use of this stable nanomicellar ophthalmic solution in the treatment of dry eye.[French]
L'invention concerne une solution ophtalmique nanomicellaire stable comprenant de la cyclosporine et un procédé de préparation de ladite solution nanomicellaire. La présente invention concerne en outre une solution nanomicellaire stable comprenant une forme de cyclosporine avec des pics de diffraction par rayons X caractéristiques à 6,9 ; 7,8 ; 9,4 et 15,9 en 2 thêta (degrés) ou de la cyclosporine amorphe. La présente invention concerne également l'utilisation de cette solution ophtalmique nanomicellaire stable dans le traitement de la kératoconjonctivite sèche.